Selenitetriglycerides-Redox-active agents.

Background: Human prostate cancer (hPCa) is the most commonly diagnosed cancer in elderly men and is the second leading cause of male cancer death. Data from epidemiological, eco-environmental, nutritional prevention and clinical trials suggest that selenium Se(IV) can prevent prostate cancer. Selol, a new organic semisynthetic derivative of Se(IV), is a mixture of selenitetriglycerides.

Comparison of selected gene expression profiles in sensitive and resistant cancer cells treated with doxorubicin and Selol.

Aim Of The Study: Cellular resistance is strongly correlated with the risk of failure in doxorubicin (DOX) treatment, and the knowledge of the mechanisms of resistance and its possible modulation is still very limited.

Material And Methods: In this study, we assessed the effect of 5% Selol and DOX on the expression of genes that affect cell proliferation in the resistant KB-V1 and sensitive HeLa cell lines, using RT2 ProfilerTM PCR Array matrix "Human Cancer Drug Resistance and Metabolism" (SABiosciences).

Results: We showed that HeLa and KB-V1 cell lines, characterised by varying susceptibility to DOX, have different genetic profiles as regards the studied genes.

The influence of Selol on the expression of oxidative stress genes in normal and malignant prostate cells.

Selol is a mixture of selenitriglycerides, obtained by the chemical modification of sunflower oil, which contain selenium at the +4 oxidation state. The aim of the present study was to describe the changes in the expression of genes related to oxidative stress caused by Selol in prostate cells: both normal (PNT1A) and malignant (LNCaP). The changes in gene expression in PNT1A and LNCaP cell lines under the influence of Selol were measured using a 96-well RT(2) Profiler ™PCR Array: Human Oxidative Stress and Antioxidant Defense, which arrayed 84 genes functionally involved in the cellular oxidative stress response.